Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC)

INTRODUCTION: PDAC is a lethal malignancy with a clear unmet need; almost all patients fail 1(st), 2(nd), and 3(rd) line multi-agent cytotoxic chemotherapy. The mammalian target of rapamycin (mTOR) has been identified as a key signaling node enhancing tumor survival and drug resistance in PDAC, henc...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Expert Opin Investig Drugs
Päätekijät: Babiker, Hani M, Karass, Michael, Recio-Boiles, Alejandro, Chandana, Sreenivasa R, McBride, Ali, Mahadevan, Daruka
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2019
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6681663/
https://ncbi.nlm.nih.gov/pubmed/31215251
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/13543784.2019.1632289
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia